Teva Pharmaceutical Industries ADR (TEVA)

Jan 13, 2025, 2:00 PM EST - 4 days ago

Teva Pharmaceutical Industries Limited (TEVA) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)

Jan 13, 2025, 1:03 PM EST - 4 days ago

Teva Pharmaceuticals CEO talks Trump and US healthcare

Jan 13, 2025, 10:35 AM EST - 4 days ago

Teva CEO on Drug Pricing, Generics, Supply Shortages

Jan 13, 2025, 1:00 AM EST - 5 days ago

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to Eylea® (aflibercept) in major parts of Europe and in Israel

Jan 10, 2025, 8:30 AM EST - 7 days ago

Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States

Dec 27, 2024, 3:21 PM EST - 21 days ago

Duvakitug And Teva's Growth: A Game Changer In Pharma

Dec 23, 2024, 4:30 PM EST - 25 days ago

Teva to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 20, 2024, 4:30 PM EST - 4 weeks ago

Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025

Dec 18, 2024, 2:29 PM EST - 4 weeks ago

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Dec 18, 2024, 4:32 AM EST - 4 weeks ago

TEVA stock soars 26%: What's going on with Teva Pharmaceuticals?

Dec 17, 2024, 4:50 PM EST - 4 weeks ago

Overlooked Stock: TEVA

Dec 17, 2024, 2:25 PM EST - 4 weeks ago

Positive Test Results Reported for Teva-Sanofi Drug for Ulcerative Colitis, Crohn's

SNY

Dec 17, 2024, 11:51 AM EST - 4 weeks ago

Teva Soars, Sanofi Gains on Strong Trial Results for IBD Treatment

SNY

Dec 17, 2024, 9:16 AM EST - 4 weeks ago

Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?

SNY

Dec 17, 2024, 7:35 AM EST - 4 weeks ago

Teva, Sanofi say drug to treat IBD met primary targets

SNY

Dec 17, 2024, 7:30 AM EST - 4 weeks ago

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn's Disease

Dec 6, 2024, 8:00 AM EST - 6 weeks ago

Can Teva Return To All-Time Highs?

Dec 5, 2024, 6:39 PM EST - 6 weeks ago

Pharma firm Teva to divest its business venture in Japan

Dec 5, 2024, 6:00 PM EST - 6 weeks ago

Teva Announces Agreement to Divest Teva-Takeda, its Business Venture in Japan

Dec 5, 2024, 1:23 PM EST - 6 weeks ago

Teva Pharmaceutical Industries Limited (TEVA) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript

Dec 4, 2024, 2:00 AM EST - 6 weeks ago

Teva Presents Positive Efficacy and Safety Data of AJOVY® (fremanezumab) for the Prevention of Episodic Migraine in Children and Adolescents from Phase 3 SPACE Trial

Nov 25, 2024, 6:00 PM EST - 7 weeks ago

Teva to Present at the 7th Annual Evercore ISI HealthCONx Conference

Nov 19, 2024, 10:25 AM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)

Nov 8, 2024, 4:30 PM EST - 2 months ago

Teva to Present at the Jefferies London Healthcare Conference

Nov 6, 2024, 11:42 AM EST - 2 months ago

Teva Pharmaceutical Industries Limited (TEVA) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:06 AM EST - 2 months ago

Teva Pharm CEO says will work productively with Trump administration

Nov 6, 2024, 7:27 AM EST - 2 months ago

Teva Pharmaceutical third-quarter profit, revenue top estimates

Nov 6, 2024, 7:00 AM EST - 2 months ago

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Nov 1, 2024, 3:05 PM EDT - 2 months ago

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

Nov 1, 2024, 3:00 PM EDT - 2 months ago

Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as Results of Real-World Analyses of UZEDY® (risperidone)

Oct 31, 2024, 9:26 AM EDT - 2 months ago

Teva Fined Around $500 Million Over MS Drug Competition Concerns

Oct 31, 2024, 7:30 AM EDT - 2 months ago

Teva Statement on European Commission Decision; Company to Appeal

Oct 31, 2024, 6:52 AM EDT - 2 months ago

Teva fined $503 mln by EU for disparaging rival product

Oct 23, 2024, 12:59 AM EDT - 3 months ago

Teva: Great Time To Buy Leading Generic Drugmaker With Growth Indicators And Lower Debt

Oct 22, 2024, 7:00 AM EDT - 3 months ago

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Oct 21, 2024, 4:17 PM EDT - 3 months ago

3 Attractive Biotechs With Recent Positives

EXEL FOLD MRK XBI

Oct 17, 2024, 11:07 AM EDT - 3 months ago

Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug

FOLD

Oct 10, 2024, 5:19 PM EDT - 3 months ago

Teva Pharmaceuticals to Pay $450 Million to Settle Kickback Allegations

Oct 10, 2024, 4:18 PM EDT - 3 months ago

Teva agrees to pay $450m to resolve kickback allegations, US Justice Dept says

Oct 8, 2024, 7:00 AM EDT - 3 months ago

Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA

Oct 3, 2024, 8:30 AM EDT - 3 months ago

Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate

Oct 1, 2024, 8:29 AM EDT - 3 months ago

Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.

Sep 30, 2024, 4:30 PM EDT - 3 months ago

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Sep 23, 2024, 2:00 AM EDT - 4 months ago

Medincell's Partner Teva Presented New Efficacy, Safety, and Tolerability Data from Pivotal Phase 3 of Olanzapine LAI for Adult Patients Diagnosed with Schizophrenia

Sep 23, 2024, 2:00 AM EDT - 4 months ago

Medincell's Partner Teva Provided Treatment Insights into Switching to UZEDY® from Perseris®

Sep 23, 2024, 1:00 AM EDT - 4 months ago

Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia

Sep 21, 2024, 4:15 AM EDT - 4 months ago

Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia

Sep 21, 2024, 4:10 AM EDT - 4 months ago

New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)

Sep 19, 2024, 10:25 AM EDT - 4 months ago

Teva Pharmaceutical Industries Limited (TEVA) Bank of America Global Healthcare Conference (Transcript)

Sep 11, 2024, 4:30 PM EDT - 4 months ago

Teva to Present at the Bank of America 2024 Global Healthcare Conference